Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 200 participants.

Also called NCT01529541

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01529541
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01529541. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
Acronym
CWP-DIANA-302
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Anagliptin
Intervention (Drug)
Sitagliptin
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01529541
Content hash
b532d72675c581d7ec6cd0e64eae5c010bce171ee76c4f9965fa3c1483ba2c2c